WO2003029284A1 - Anti-hiv agent - Google Patents

Anti-hiv agent Download PDF

Info

Publication number
WO2003029284A1
WO2003029284A1 PCT/JP2002/010119 JP0210119W WO03029284A1 WO 2003029284 A1 WO2003029284 A1 WO 2003029284A1 JP 0210119 W JP0210119 W JP 0210119W WO 03029284 A1 WO03029284 A1 WO 03029284A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
terminated
modular
modular structure
composite
Prior art date
Application number
PCT/JP2002/010119
Other languages
French (fr)
Japanese (ja)
Inventor
Nobutaka Fujii
Akira Otaka
Masao Matsuoka
Original Assignee
Nobutaka Fujii
Akira Otaka
Masao Matsuoka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobutaka Fujii, Akira Otaka, Masao Matsuoka filed Critical Nobutaka Fujii
Publication of WO2003029284A1 publication Critical patent/WO2003029284A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

A polypeptide containing at least one of the following modular structures (1) to (3) and having the ability to bind to the N36 of human immunodeficiency virus; a composite thereof; and an anti-HIV agent or preventive or remedy for AIDS which contains the polypeptide or composite. (Y')m1-X1aX1b-A1-X1cX1dX1e-A2-(X')n1 : modular structure 1 (MS1) (Y')m2-X2a-A1A1-X2bX2c-A2A2-(X')n2 : modular structure 2 (MS2) (Y')m3-X3a-A1-X3bX3cX3d-A2-X' : modular structure 3 (MS3) {In the modular structures, A1 represents an acidic amino acid; A2 represents a basic amino acid; X1a to X3d are the same or different and each represents any desired amino acid; X' represents any desired amino acid which may have a protective group or represents -OR1 or -NR2R3; X' represents -OR4 or -NR5R6 (R1 to R6 are the same or different and each represents hydrogen, alkyl, aryl, or aralkyl); Y' represents hydrogen, R7CO- (R7 represents alkyl, optionally substituted phenyl, or optionally substituted benzyl), toluenesulfonyl, or methanesulfonyl; n1 and n2 each is 1 when MS1 and MS2 are terminated by carbon, and each is 0 when MS1 and MS2 are not terminated by carbon; m1 to m3 each is 1 when MS1, MS2, and MS3 are terminated by nitrogen, and each is 0 when MS1, MS2, and MS3 are not terminated by nitrogen; and in the modular structures (1) to (3) the amino acids each means -NH-CH(R')-CO- (R' represents a side chain of the amino acid).}
PCT/JP2002/010119 2001-09-27 2002-09-27 Anti-hiv agent WO2003029284A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-297963 2001-09-27
JP2001297963 2001-09-27

Publications (1)

Publication Number Publication Date
WO2003029284A1 true WO2003029284A1 (en) 2003-04-10

Family

ID=19118944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010119 WO2003029284A1 (en) 2001-09-27 2002-09-27 Anti-hiv agent

Country Status (1)

Country Link
WO (1) WO2003029284A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013242A1 (en) * 2006-07-27 2008-01-31 Gekkeikan Sake Co., Ltd. Method for production of n36-binding peptide
JP2020517741A (en) * 2017-04-18 2020-06-18 インスティテュート オブ パソジェン バイオロジー，チャイニーズ アカデミー オブ メディカル サイエンシズ Lipopeptide, its derivative, its pharmaceutical composition and its use for potently inhibiting HIV
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006599A1 (en) * 1998-07-30 2000-02-10 Whitehead Institute For Biomedical Research Inhibitors of hiv membrane fusion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006599A1 (en) * 1998-07-30 2000-02-10 Whitehead Institute For Biomedical Research Inhibitors of hiv membrane fusion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MALASHKEVICH VLADIMIR N. ET AL.: "Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides", PROC. NATL. ACAD. ASCI. USA, vol. 95, no. 16, 4 August 1998 (1998-08-04), pages 9134 - 9139, XP002170630 *
SHIBO JIANG ET AL.: "A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 270, no. 1, 2000, pages 153 - 157, XP001121493 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013242A1 (en) * 2006-07-27 2008-01-31 Gekkeikan Sake Co., Ltd. Method for production of n36-binding peptide
JP2020517741A (en) * 2017-04-18 2020-06-18 インスティテュート オブ パソジェン バイオロジー，チャイニーズ アカデミー オブ メディカル サイエンシズ Lipopeptide, its derivative, its pharmaceutical composition and its use for potently inhibiting HIV
JP7057822B2 (en) 2017-04-18 2022-04-20 インスティテュート オブ パソジェン バイオロジー，チャイニーズ アカデミー オブ メディカル サイエンシズ Lipopeptides for strongly inhibiting HIV, derivatives thereof, pharmaceutical compositions thereof and their use
US11680086B2 (en) 2017-04-18 2023-06-20 Shanxi Kangbao Biological Product Co., Ltd. Lipopeptide for potently inhibiting HIV, derivative thereof, pharmaceutical composition thereof and use thereof
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Similar Documents

Publication Publication Date Title
ATE196507T1 (en) METHOD FOR PRODUCING VIRAL VECTORS OF AT LEAST 20KB BY INTERMOLECULAR HOMOLOGOUS RECOMBINATION IN A PROKARYOTIC CELL
RS100504A (en) Hepatitis c virus inhibitors
IL172015A (en) Pyrimidine compounds having phosphonate groups, method for their preparation and their use in the manufacture of medicaments for treating viral infection
FI901739A0 (en) BENSIMIDAZOLER, DESSA FOERENINGAR INNEHAOLLANDE CEILING MODEL OCH FOERFARANDE FOER DERAS FRAMSTAELLNING.
ATE154363T1 (en) SYNTHETIC POLYPEPTIDES AS INHIBITORS OF HIV-1
ATE30720T1 (en) NEW DIHYDROPYRIMIDINES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE IN PHARMACEUTICALS.
MY111814A (en) Watersoluble azole antifungals
ATE293171T1 (en) RETROVIRAL HYBRID VECTORS PSEUDOTYPED WITH LCMV GLYCOPROTEIN
CA2243544A1 (en) 7-amino-2-heptenoates and their use in the preparation of methylphenidate
CA2146877A1 (en) Sulphonyl amino carbonyl triazolinones
TR200000721T2 (en) Vitronectin receptor antagonists.
WO2003029284A1 (en) Anti-hiv agent
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
AU8912891A (en) Biologically active amines
FI20010045A (en) Cyclopentane and pentene beta-amino acids
BR0312889A (en) Pegged t20 polypeptide
ATE386728T1 (en) CYCLIC UREA COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
EP0381340A3 (en) Peptides with sulphate ester groups
NO981393D0 (en) Guanidinoproteasehemmere
WO2004076474A3 (en) Polyethylene glycol modified interferon compositions and methods of use thereof
AU7383387A (en) Amino acid derivatives
DE69303583T2 (en) 15-Deoxyspergualin-like compounds, processes for their preparation and their use as therapeutic agents for suppressing the immune system
WO2003097585A3 (en) Amidoacetonitrile compounds
AU1465301A (en) Process for preparing n-(4-hydroxy-phenyl)-n'-(4'-aminophenyl)-piperazine
DE502004002562D1 (en) PROCESS FOR THE PRODUCTION OF HIGH-PURITY POLYALKYLENE GLYCOLS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS KE KG KR KZ LC LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase